QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics

     QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the
          Development and Commercialization of Companion Diagnostics

PR Newswire

GERMANTOWN, Maryland and HILDEN, Germany, February 13, 2013

GERMANTOWN, Maryland and HILDEN, Germany, February 13, 2013 /PRNewswire/ --

  oArrangement to facilitate future collaborations in personalized medicine
  oProvides framework to develop and commercialize QIAGEN companion
    diagnostics paired with Lilly medicines in an effort to improve outcomes
    for individual patients
  oBuilds on the two companies' recent mutual successes

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has
entered into a master collaboration agreement with Eli Lilly and Company
(NYSE: LLY) for the development and commercialization of companion diagnostics
for pairing with Lilly investigational and approved medicines across all
therapeutic areas. The agreement builds on QIAGEN and Lilly's past work
together. Companion diagnostics unlock a patient's molecular information in
order to guide treatment decisions for specific cancers or other diseases.
Financial terms of the agreement are not being disclosed.

The agreement provides a framework for Lilly and QIAGEN to collaborate on
future projects - across all of Lilly's therapeutic areas - aimed at bringing
to market Lilly medicines paired with QIAGEN diagnostics. It also further
underscores QIAGEN's leading position in partnering with global pharmaceutical
companies to deliver the benefits of personalized medicine to patients and
healthcare providers.

"Tailored therapies are a key component of Lilly's strategy of providing
improved outcomes for individual patients. By working with partners like
QIAGEN, we are advancing a number of tailored therapeutics in an effort to
target the right medicine to the right patient," said Daniel Skovronsky, M.D.,
Ph.D., vice president, tailored therapeutics, Lilly, and chief executive
officer, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. "This
collaboration with QIAGEN extends our capabilities to more quickly and
cost-effectively bring innovative new medicines, alongside advanced
diagnostics, to patients worldwide who are waiting."

"We have expanded this relationship with Lilly as a result of our ongoing work
together," said Dr. Ulrich Schriek, Senior Vice President Global Business
Development of QIAGEN. "This agreement lays the groundwork for potential
future projects with Lilly in various therapeutic areas and enables
significant efficiencies for future development programs by standardizing
interfaces and processes between our organizations. Through partnerships like
this, QIAGEN offers pharma companies a cost-effective way to maximize the
value and benefits of potential new medicines in their pipelines, while also
reducing the risks in medicine development."

QIAGEN is at the forefront globally in developing and validating Personalized
Healthcare tests that provide physicians with genomic information on each
patient to guide the selection of medicines in treating cancer and other
diseases. QIAGEN is actively expanding its pipeline of tests for important
biomarkers and intends to submit several companion diagnostics for U.S.
regulatory approval. Last month, QIAGEN announced submission of its
therascreen^® EGFR RGQ PCR Kit test to the FDA as a proposed companion
diagnostic to guide treatment with a new investigational oncology compound
developed by Boehringer Ingelheim. QIAGEN is engaged in more than 15 projects
with leading pharmaceutical and biotech companies to co-develop and market
companion diagnostics.

QIAGEN and Lilly have previously collaborated on companion diagnostics
designed to run on QIAGEN's Rotor-Gene Q system, a component of the
QIAsymphony family of automated instruments, which is revolutionizing
laboratory workflows. QIAGEN's strategy is to develop FDA-approved diagnostics
in the United States for use on this platform.

Photos on Personalized Healthcare are available online for free download at:


QIAGEN N.V., a Netherlands holding company, is the leading global provider of
Sample & Assay Technologies that are used to transform biological materials
into valuable molecular information. Sample technologies are used to isolate
and process DNA, RNA and proteins from biological samples such as blood or
tissue. Assay technologies are then used to make these isolated biomolecules
visible and ready for interpretation. QIAGEN markets more than 500 products
around the world, selling both consumable kits and automation systems to
customers through four customer classes: Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharmaceutical and biotechnology companies) and Academia (life
sciences research). As of December 31, 2012, QIAGEN employed approximately
4,000 people in more than 35 locations worldwide. Further information can be
found at http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of
theU.S.Securities Act of 1933, as amended, and Section 21E of
theU.S.Securities Exchange Act of 1934, as amended. To the extent that any
of the statements contained herein relating to QIAGEN's products, markets,
strategy or operating results, including without limitation its expected
operating results, are forward-looking, such statements are based on current
expectations and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks associated
with management of growth and international operations (including the effects
of currency fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer classes, the
commercial development of markets for our products inapplied testing,
personalized healthcare, clinical research,proteomics, women's
health/HPVtesting andnucleic acid-basedmolecular diagnostics; changing
relationships with customers, suppliers and strategic partners; competition;
rapid or unexpected changes in technologies; fluctuations in demand for
QIAGEN's products (including fluctuations due to general economic conditions,
the level and timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties in
successfully adapting QIAGEN's products to integrated solutions and producing
such products; the ability of QIAGEN to identify and develop new products and
to differentiate and protect our products from competitors' products; market
acceptance of QIAGEN's new products, the consummation of acquisitions, and the
integration of acquired technologies and businesses. For further information,
please refer to the discussions in reports that QIAGEN has filed with, or
furnished to, theU.S.Securities and Exchange Commission (SEC).

Public Relations:
Dr. Thomas Theuringer
Director Public Relations
Email: pr@qiagen.com


Investor Relations:
John Gilardi
VP Corporate Communications

Peter Vozzo
Director, Global Investor Relations
Email: ir@qiagen.com


SOURCE Qiagen N.V.
Press spacebar to pause and continue. Press esc to stop.